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Abstract 
Purpose: To evaluate the curative effect of corticosteroids in the treatment of acute pain, local edema, 
and skin lesions caused by herpes zoster, and to develop some pertinent therapeutic guidelines.  
Methods: A total of 48 cases of patients diagnosed with herpes zoster from 2010 to 2011 in the 
dermatology clinic of Shan Dong Traffic Hospital were selected and all received the same therapy of 
antiviral, pain-relieving and nerve nutrition. They were divided into a corticosteroid application group, 
with 24 patients treated with corticosteroids, and a control group of 24 patients without corticosteroids. 
Local swelling subsided in the corticosteroid group. The differences observed in pain relief and days 
needed for blisters to dry and scab between the two patient groups were analyzed to determine 
significance and, thus, assess the curative effect of corticosteroids in treatment of herpes zoster.  
Results: Patients in the glucocorticosteroid application group relieved pain faster than patients in the 
control group (2.38 ± 1.41 days vs 5.50 ± 3.19 days), and the difference was significant (p < 0.05). Skin 
lesions of patients in the glucocorticosteroid application group healed quicker than that of patients in 
control group (2.83 ± 0.87 days vs 3.54 ± 1.02 days), and the difference was remarkable (p < 0.05). 
Local swelling of patients in the glucocorticosteroid application group recovered rapidly after treatment. .  
Conclusion: Treatment of herpes zoster with appropriate corticosteroid isodose application can 
effectively relieve acute pain and local swelling, and speed up scabbing and healing of skin lesions. 
 
Keywords: Herpes zoster, Corticosteroids, Local edema, Scab, Skin lesions, Acute pain, Blisters, 
Therapeutic guidelines 
 
Tropical Journal  of Pharmaceutical Research is indexed by Science Citation Index (SciSearch), Scopus, 
International Pharmaceutical Abstract, Chemical Abstracts, Embase, Index Copernicus, EBSCO, African 
Index Medicus, JournalSeek, Journal Citation Reports/Science Edition, Directory of Open Access Journals 




Herpes zoster is caused by varicella-zoster virus 
(VZV), and is characterized by clusters of small 
blisters distributed along unilateral peripheral 
nerves and accompanied by obvious neurodynia. 
At present, VZV is known as human herpes virus 
3 (HHV-3), is brick-shaped and has a 
stereoscopic and symmetrical capsid enclosing 
double-stranded DNA, and only one serotype 
has been described. Herpes zoster usually has a 
2-3 weeks duration, although it may have a 3-4 
weeks course in the elderly. Temporary light 
erythema or pigmentation is usually left after 
drying up and scabbing of blisters [1]. Herpes 
zoster is accompanied by neuralgia before rash, 
during rash, and after healing of skin lesions, 
which is called zoster-associated pain. If 
neuralgia continues after skin lesions subside 
(usually 4 weeks later), it is known as herpes 
zoster postherpetic neuralgia. Herpes zoster can 
be diagnosed according to its typical clinical 
manifestations. Its therapeutic principles include 
antiviral, pain-relieving, and anti-inflammatory 
treatment, and prevention of complications. 
Recently, it has been widely accepted that early 
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and adequate anti-virus treatment can relieve 
neuralgia and shorten the length of the disease. 
  
Historically, there has been a dispute over the 
application of corticosteroids in herpes zoster. 
Andrews' Diseases of the Skin [2] indicates that 
corticosteroids have an immunosuppressive 
effect, which may lead to epidemic diffusion, 
blood infection, and obstacles to recovery from 
disease. However, others recommend that 
corticosteroids can be used as an adjuvant 
therapy.  
 
On the premise of standard antiviral therapy, 
through controlling inflammatory reactions, a low 
dose of corticosteroids in early stages [3] could 
reduce tissue edema, relieve pain, prevent toxic 
effects and destructive effects to ganglion and 
nerve fiber, inhibit fibrosis processes, prevent 
postherpetic neuralgia, and not affect production 
of the body's immunoglobulin (IgG) for fighting 
disease. A clinical trial [4] has shown that 
applying prednisone with acyclovir can relieve 
pain, promote healing of skin lesions, and 
shorten courses of acute neuritis so as to 
improve the quality of life of patients. However, it 
does not reduce the occurrence rate of 
postherpetic neuralgia. 
 
Corticosteroids can reduce tissue edema, relieve 
pain, and accelerate healing of skin lesions by 
controlling inflammatory reactions. However, 
because corticosteroids can inhibit part of the 
body’s immune function, cause disorders of 
water and electrolyte metabolism, and result in 
osteoporosis, they can be misused and infection 
can be induced or aggravated. Hence, 
corticosteroids should be selectively and 
cautiously applied to herpes zoster patients, and 
combined with adequate antiviral therapy. 
 
At present, some propose that, on the premise of 
no contraindications, patients with obvious 
edema and acute pain in their head, face 
trigeminal nerve and local inflammation, who 
were elderly with severe pain, or with herpes 
zoster accompanied with local nerve dysfunction 
as well as Ramsay-Hunt syndrome (facial 
paralysis, earache, external auditory canal 
herpes triad) could be applied moderate-doses of 
corticosteroids in early stages, and the 
application result in improved living quality [5,6]. 
 
To further examine the curative effect of 
corticosteroids in the treatment of herpes zoster, 
24 cases of herpes zoster patients treated with 
corticosteroids and another 24 cases of patients 
treated without corticosteroids were studied. 
Their pain, local edema and recovery condition of 
skin lesions were analyzed and statistical 
comparisons were made. This further exploration 
of the contraindication, indication, dosage and 
course of treatment of corticosteroids in the 
treatment of herpes zoster provides additional 






A total of 48 cases of patients diagnosed with 
herpes zoster from 2010 to 2011 in the 
dermatology clinic of Shandong Traffic Hospital 
were selected. Patients were divided into a 
corticosteroid application group and a control 
group (no corticosteroid treatment) in terms of 
their medication. Among the 24 cases in the 
corticosteroid application group (male 13, female 
11), all had obvious edema and acute pain in 
their head and face from herpes zoster and local 
inflammation.  
 
Of those who had wide skin lesions, large areas 
of blisters and blood blisters, their pain score was 
above 5. There were five patients with obvious 
local edema in this group. Patients had not 
received antiviral drugs before treatment. 
Patients who were severely infected or had 
cardiopulmonary disease as well as those with 
immune suppression and connective tissue 
diseases, with a long-term use of corticosteroids, 
were all excluded. 
 
According to limiting factors such as age, rash 
days before hospital visit, not previously affected, 
underlying disease, and immunity, 24 cases 
(male 13, female 11) of herpes zoster patients in 
the control group were treated without 
corticosteroids. The age of patients in the two 
groups ranged from 33 to 85 years. All patients 
were informed and signed informed consents 
before study enrollment, and consented to the 
use of their samples for molecular and 
pathological analyses. 
 
This clinical study was strictly carried out in 
accordance with the Helsinki declaration [7], and 
was approved by the ethical committee of 
Shandong Jiaotong Hospital （Research registry 




Patients in two groups were administered 500 
mg of acyclovir by intravenous drip and received 
anti-virus twice each day. Mecobalamin was 
taken as 1 tablet, three times a day. Fursultimine 
was taken as 2 tablets, three times per day for 
Zhang & Xu 
Trop J Pharm Res, August 2016; 15(8): 1741  
 
trophic nerve pain. Carbamazepine was taken 
orally as 1 tablet, once per day to relieve pain. 
He-Ne laser radiation was used for irradiation for 
15 min, once a day. Povidone iodine was used 
externally, 3 times a day. Depending on local 
inflammation and pain severity, the corticosteroid 
application group was given 2 prednisone tablets 
(or methylprednisolone tablets) twice or three 
times a day, for a 7-day course. 
 
Evaluation and scoring parameters 
 
The Numerical Rating Scale (NRS) was used for 
pain assessment. Namely, on a 0-10 pain scale, 
0 represented no pain at all, 1-2 points 
represented mild pain, 3-4 points represented 
moderate pain, 5 points represented a medium 
degree of pain, 5-7 points represented moderate 
to severe pain, 8-9 points represented a serious 
degree of pain, and 10 points represented the 
most acute pain imaginable. 
 
Substantial pain relief was defined as:  
[(NRS score when admitted to hospital-
immediate NRS score)/NRS score when 
admitted to hospital] X 100 % was ≥ 50 %. 
 
Local swelling was defined as subsided when:  
Patients made a self-assessment of swelling and 
determined that the local appearance had 
returned to normal. 
 
Healing of skin lesions was defined as:  





The times for substantial pain relief and healing 
of skin lesions were recorded. Statistical 
analyses were conducted to determine whether 
there were statistical differences in times for pain 
relief and healing of skin lesions between the two 
groups. Also, the times for swelling recovery of 
the five patients with obvious local swelling in the 
corticosteroid application group were recorded. 
After a comprehensive analysis of the above 
results, the curative effect of corticosteroids in 




Data obtained were analyzed using SPSS ver. 
19.0. Data conforming to normal distribution were 
expressed as mean ± SD. Skew-distributed data 
were expressed as median. Comparison 
between groups was performed using analysis of 
variance (ANOVA) for repeated measurement 
and t-test. Enumeration data were compared 
using Chi-square test. 
RESULTS 
 
Time preceding pain relief in the 
corticosteroid versus control group 
 
Seven patients in the corticosteroid group had 
obvious pain relief after one day of treatment. 
Four patients after two days and nine patients 
after three days had obvious pain relief. After 4, 5 
and 6 days of treatment, one patient had obvious 
pain relief, while another had no pain relief after 
treatment. 
 
One patient in the control group had pain relief 
after 2 days of treatment. The same results were 
observed for two patients after 3 days, four 
patients after 4 days, seven patients after 5 days, 
and five patients after 6 days of treatment. After 
7, 9, 10, and 17 days, only one patient 
experienced pain relief, respectively, while one 
patient had no pain relief after treatment. 
Compared with the control group, the time 
needed for patients to get pain relief in the 
corticosteroid application group was obviously 
shorter (p < 0.05). Details are shown in Figure 1. 
Compared with the control group, the time 
needed for healing of skin lesions and rash relief 
in glucocorticosteroid application group was 





One patient in the corticosteroid application 
group had blisters drying up and scabbing after 
one day of treatment. The same result appeared 
in eight patients after 2 days, 9 patients after 3 
days, and six patients after 4 days of treatment. 
One patient in the control group had blisters 
drying up and scabbing after one day of 
treatment. The same result was observed for two 
patients after 2 days, eight patients after 3 days, 
nine patients after 4 days, and four patients after 
5 days of treatment. Compared with the control 
group, the time preceding skin lesion scabbing 
and healing in the corticosteroid application 
group was shorter (p < 0.05). Please refer to 




Herpes zoster caused by VZV clinically presents 
as neuralgia and papule, blisters distributed 
along peripheral nerves, inflammatory response, 
and even local swelling when the response is 
severe, which has seriously influenced the 
quality of life in some patients [8,9].  
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Figure 1: Time (days) preceding pain relief in the corticosteroid application and control groups 
 
 
Figure 2: Rash recovery in the corticosteroid application and control groups after treatment 
  
Table 1: Statistical data for corticosteroid curative effect on pain and skin lesions 
 
Group  No. of cases  Obvious pain 
relief(days)* 
Blisters dried up  
and scabbed (days)* 
Corticosteroid 24 2.38±1.41 2.83±0.87 
Control  24 5.50±3.19 3.54±1.02 
Sig.(bilateral) - 0.000 0.013 
P - <0.05 <0.05 
Data are expressed as mean + standard deviation (SD) 
 
Therefore, pain relief, local swelling alleviation, 
and local skin lesion improvement are important 
factors in the treatment of herpes zoster. 
 
At present, the commonly used anti-viral drugs 
for treating herpes zoster are acyclovir and 
famciclovir, while the commonly used pain killers 
are carbamazepine, neurotropin, saridon, 
tramadol, mecobalamin, and fursultimine, which 
are applied for neurotrophic treatment. Some 
reported studies have demonstrated that 
combining corticosteroids with sufficient anti-
virus treatment can significantly relieve acute 
pain of herpes zoster and speed up healing of 
skin lesions, thus improving the quality of life of 
patients. However, the combinational therapy 
was not shown to prevent postherpetic neuralgia 
[10].  
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Twenty four cases of patients treated with 
corticosteroids and 24 cases of patients treated 
without corticosteroids were examined in this 
retrospective study. Statistical analysis of days 
needed for obvious pain relief, as well as skin 
lesion healing and scabbing, was conducted. In 
addition, subsiding of local swelling of five 
patients in the corticosteroid application group 
was observed, in order to confirm the curative 
effect of corticosteroids combined with anti-
retrovirus treatment of herpes zoster. 
 
VZV infection can cause obvious inflammatory 
responses in local nerve fibers and the skin. 
Local inflammatory responses to the infection 
may include increased vessel permeability and 
leakage, tissue damage, intercellular structure 
damage, local swelling, and blisters [11,12]. 
Corticosteroids have a strong anti-inflammatory 
effect by inducing inflammation-inhibiting protein 
element 1, and inhibiting inducible nitric oxide 
synthase (iNOS) and cyclooxygenase-2 (COX-2). 
It acts by intervening complement activation and, 
thus, reducing the production of inflammatory 
mediators; stabilizing lysosomal membranes and 
inhibiting the release of lysosomal enzymes, so 
as to alleviate tissue injury; and decrease the 
permeability of capillaries and inhibit infiltration 
and activity of phagocytic leukocytes, whereby 
inflammatory cellapoptosis can be induced and 
the release of inflammatory mediators is reduced 
[13]. In this way, the exosmosis of cells and body 
fluids can be eased, local swelling can be 
alleviated, and healing of skin lesions can be 
stimulated. 
 
Recently, prednisone tablets have been 
suggested by emedicine (the world's largest 
original medical literature and a clinical 
knowledge database of Tong Ji reviews 
literature, providing doctors with a clinical 
decision support tool with easy operation and 
high authority) to take orally once a day, 10 - 50 
mg, in the treatment of herpes zoster [14].  
 
Interactions between drugs should be considered 
while taking prednisone. For instance, the half-
life of prednisone will increase while using it with 
estrogen; the risk and criticality of hypokalemia 
will increase while using it with digoxin and 
digitalis; hypnotic sedative drugs, such as dilantin 
and rifampicin can speed up the metabolism of 
prednisone; and serum potassium should be 
monitored while combining sodium potassium 
diuretics with prednisone [15]. There have been 
reported no common opinions about the course 
of corticosteroids. A course of seven days was 
adopted in this retrospective study and a good 
curative effect was achieved, so this could 
provide certain guidance for treatment in the 
future. 
 
Limitations of the study 
 
Patients included in the study were not followed 
up after treatment. Also, whether 
glucocorticosteroid can prevent postherpetic 




Neuralgia, the major clinical symptom of herpes 
zoster, can influence the quality of life (QoL) of 
patients and even induce depression and 
character changes. Moreover, virus infection can 
induce intensive inflammation on nerve and skin, 
increasing vascular permeability and leading to 
swelling. Hence, relieving pain and local swelling 
are of great significance in the treatment of 
herpes zoster. Patients with obvious edema and 
acute pain in their head and facial trigeminal 
nerve and local inflammation, elderly patients 
with severe pain, or patients with herpes zoster 
accompanied by local nerve dysfunction can be 
treated with a medium dose of 
glucocorticosteroid in the early stage, and thus 
improve QoL. In this study, glucocorticosteroid 
therapy achieved good curative effect, a finding 
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